Want to do some research in rosacea and stuck for a suggestion? Well this post is for you. Below is a list of the major open questions in rosacea research. The creator of this list tells us that this list of questions need to be answered before we can claim to thoroughly understand rosacea.
- Which genes predispose patients for the development of rosacea and are responsible for the different prevalences of rosacea in various countries?
- Does prerosacea exist and what percentage of patients present with each respective subtype at disease initiation?
- What are the key molecular mediators in the earliest stages of rosacea?
- Suppression of which combination of targets is most effective at inhibiting inflammation at early stages of manifestation?
- How can triggering of inflammation and neurovascular dysregulation be blocked?
- What is the role of Demodex, microbiota and the gut–skin axis in rosacea?
- What is the exact role of Th1/Th17 cells, antibody-producing B cells, mast cells, macrophages, fibroblasts and keratinocytes in each subtype of rosacea?
- Does neuro-inflammation drive the initiation of immune activation, vice versa, or do both pathways exist depending on the trigger factor?
- What is the pathophysiological basis of fibrosis and glandular hyperplasia in rosacea, and how can it be prevented?
- Which pathways do current therapies inhibit in rosacea patients in vivo?
- How do the key molecules and therapeutic targets differ among the various subtypes?
- What are the biomarker profiles within the different subtypes of rosacea?
- How do quantitative and qualitative biomarker changes correspond to treatment outcomes?
Read the full paper here: Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics